Lucid Diagnostics
Update in progressLUCD (NasdaqCM)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryMedical Devices
Lucid Diagnostics Inc. is a commercial‑stage medical diagnostics company in the United States focused on patients with gastroesophageal reflux disease at risk of esophageal precancer and cancer, particularly esophageal adenocarcinoma. Its flagship product, the EsoGuard Esophageal DNA Test, uses samples collected with the EsoCheck device to enable early detection and prevent deaths. Founded in 2018 and based in New York, it is a subsidiary of PAVmed Inc.
Company score
- Sentiment
- 0.45
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.40
- Governance
- 0.29
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.18
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.32
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Sort by
Order by
Timeframe
No news articles are available for this company yet.
Unable to load company news.
Loading more news
You're all caught up!